US2790001A - Resolution of amino acids - Google Patents
Resolution of amino acids Download PDFInfo
- Publication number
- US2790001A US2790001A US472211A US47221154A US2790001A US 2790001 A US2790001 A US 2790001A US 472211 A US472211 A US 472211A US 47221154 A US47221154 A US 47221154A US 2790001 A US2790001 A US 2790001A
- Authority
- US
- United States
- Prior art keywords
- solution
- acid
- aspartic acid
- glutamic acid
- optically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
Definitions
- This invention relates to a process for resolving racemic modifications of optically active compounds, and more particularly, to the resolution of racemic modifications of alpha-amino carboxylic acids.
- Glutamic acid and aspartic acid are well known optically active compounds.
- L-glutamic acid and L-aspartic acid are useful at the present time, there being no known utility for D-glutamic acid and D-aspartic acid or their racemic modification; namely, DL-glutamic acid or DL-aspartic acid.
- Chemical processes for the synthesis of glutamic acid and aspartic acid result in the formation of racemic modifications of these compounds, that is, optically neutral DL-glutamic acid and DL-aspartic acid, respectively.
- One object of the instant invention is to provide a process for the resolution of DL-alpha-amino carboxylic acids.
- Another object of the instant invention is to provide a process for the resolution of DL-glutamic acid.
- Another object of this invention is to provide a process for the resolution of DL-aspartic acid.
- Another object of this invention is to provide a process for the resolution of DL-leucine.
- a further object of this invention is to provide a commercially feasible process for the resolution of DL-alphaamino carboxylic. acids which do not require the use of expensive reagents or equipment.
- a racemic modification of an alpha-amino carboxylic acid such as, for example, aspartic acid, glutamic acid, or leucine
- an alpha-amino carboxylic acid such as, for example, aspartic acid, glutamic acid, or leucine
- the crystals thus separated comprise a quantity of an optically active form of the racemic modification originally in the solution and a quantity of the racemic modification in the unresolved state with perhaps some of the optically activecform of the resolving compound;
- the optically active form of the racemic modification being subjected to the resolution process may be separated from the other compounds by standard procedures.
- Alpha-amino carboxylic acids which are particularly useful in this invention are those having a solubility in water at room temperature of less than about 8 grams per 100 grams of water.
- Specific alpha-amino carboxylic acids, in addition to leucine, aspartic acid and glutamic acid, which may be utilized include tyrosine, isoleucine, norleucine, valine, and the like. All of these compounds may be utilized as resolving compounds or may be resolved when in their racemic modifications according to the process of this invention.
- All of these compounds are characterized as non-basic alpha-amino carboxylic acids for the reason that all contain not more .than one amino group per carboxy group
- Alpha-amino carboxylic acids containing more than one amino group per carboxygroup in the molecule, such as lysine, are not operable in this invention.
- a preferred practice of the instant invention comprises preparing an aqueous solution of a racemic modification of either aspartic acid or glutamic acid, the solution also containing an optically active form of that one of these two compounds which is not being resolved.
- a solution is prepared containing DL-aspartic acid and an optically active form of, for example, glutamic acid, that is, either L-glutamic acid or D-glutamic acid.
- a solution is prepared containing DL-glutamic acid and an optically 'active form of aspartic acid, that is, D-' aspartic acid or L-aspartic acid.
- a convenient method for preparing the solution'com prises preparing an aqueous slurry of the racemic modification and an optically active form of the resolving com-' pound for example, an aqueous slurry of DL-aspartic acid and L-glutamic acid, and adding alkali to the slurry in sufiicient amount to dissolve the solids and form a true solution.
- the solution is then adjusted to about the isoelectric point of the racemic modification by the addition of an inorganic acid, such as aqueous hydrochloric acid, and the volume of the solution is adjusted by adding or removing water so that the solution will be supersaturated with respect to the racemic modification at the isoelectric point.
- Crystallization contains between about 3% and about 5% of the racemic modification and between about 1% and about 2% of the resolving compound. The solution is then allowed to stand with gentle agitation until crystallization is complete. Crystallization is usually carried out at room temperature, but higher or lower temperatures may be utilized if desired. The crystals will cont-ain a substantial quantity of an optically active form of of the racemic modification corresponding in rotation to that of the resolving compound, and also a substantial quantity of the racemic modification.
- DL-aspartic acid and L-glutamic acid are slurried in water, and aqueous sodium hydroxide is added to the slurry with agitation until the pH of the liquid phase is adjusted, preferably to about 7.0. Under these conditionsv the DL-aspartic acid and L-glutamic acid dissolve to form a true solution. The solutionis then adjusted to about.
- pH 3.1 by'the addition of concentrated aqueous hydrochloric acid, and the volumeof the solution is adjusted It is desirable that the solution being subjected armour by adding or removing (by evaporation) water so that the solution at pH 3.1 will be supersaturated with respect to DL-aspartic acid.
- the solution is then allowed to stand with gentle agitation for about 72 hours at room temperature and filtered.
- the crystals obtained comprise about 45% DL-aspartic acid, about 40% of D-aspartic acid, and about 15% QtL-gIutamic acid.
- the filtrate contains about 63% of the DL-aspart-ic acid originally in solution, about 8% L-aspartic acid (based upon total solids in solution) and about 90% of the L-glutamic acid originally added.
- the crystallization be carried out at a temperature of about room temperature or below, but higher temperatures may be utilized for particular purposes.
- the solution of the racemic modification and the resolving compound may be prepared in any convenient manner so long as the solution upon adjustment to about the isoelectric point of the racemic modification is supersaturated with respect to the racemic modification. It is not necessary that the resolving compound be at its-saturation concentration at the time of crystallization if less than optimum resolution is permissible. The best yields, however, are obtained if the resolving compound is at its saturation concentration at the time that crystallization begins. Crystallization is carried out until the formation of crystals discontinues, that is, until equilibrium conditions obtain or are substantially achieved.
- resolving compound refers to an optically active form of either glutamic acid or aspartic acid, or similar non-basic alpha-amino carboxylic acid, for example, L-aspartic acid, D-aspartic acid, L-glutamic acid, or D-glutamic acid, etc.
- the resolving compound is preferably either L-glutamic acid or D-glutamic acid.
- the resolving compound is preferably L-aspartic acid or D- aspartic acid.
- the .filtrate amounted to 240 parts and contained :the following solids:
- the L-aspartic acid was isolated from the filtrate by first separating L-glutamic acid by crystallization of L- glutamic acid hydrochloride, adjusting the pH to 3.1 and erystallizing L-aspartic acid.
- Example 11 Twelve parts DL-aspartic acid and 8 parts L-glutamic acid were slurried in Water and dissolved by adjusting the pH of the aqueous phase to about 7.0 by the addition of a 50% aqueous solution of sodium hydroxide. The solution was then adjusted to pH 3.2 by the addition of 30% aqueous hydrochloric acid, and the weight of the solution was then adjusted to 400 parts by adding water. The solution was allowed to stand with gentle agitation for about 72 hours and then filtered to remove the crystals which had formed. The crystals amounted to 3.5 parts and had the following compositions:
- optically active forms of aspartic acid and glutamic acid were recovered by the procedures outlined in Example I.
- Example III About 10 parts of DL-glutamic acid and about 5 parts of L-aspartic acid were slurried in about 200 parts water. To the slurry was added a. 5 0% aqueous solution of sodium hydroxide until the pH of the aqueous phase amounted to about 7.0. Addition of the sodium hydroxide solution resulted'in dissolution of the DL-glutamic acid and L- aspartic acid to form a true solution. The solution was adjusted to pH 3.2 by the addition of 37% aqueous hydrochloric acid and then suificient water was added to the solution to adjust the weight of the solution ;to 250 parts. The solution was allowed to stand with gentle agitation for about 72 hours at room temperature and then filtered to remove the crystals which had formed. The crystals amounted to about 5 parts and had the following composition by weight:
- Percent D-glutarnic acid 10 DL-glutamic acid 78 L-aspartic acid 12 Example TV About 16.8 parts of DL-glutamic acid monohydrate and about 9 parts of L-leucine were dissolved in dilute hydrochloric acid at pH 1.0. The solution was :then adjusted to pH 3.2 by the addition of a 50% aqueous sodium hydroxide solution. The final solution amounted to about 300 parts. The solution was agitated gently over a period of about 24'hours at about 25 C. to per mit crystallization to proceed, and the crystals were re moved by filtration. The crystals amounted to 9.4 parts and comprised 1.8 parts D-glutamic acid and 7.6 parts DL-glutamic acid. The Drglutamic acid was separated from the .DL-glutamic acid by recrystallization from 300 parts of water at about 25 C.
- a process for resolving a racemic modification se lected from the group consisting of DL-aspartic acid and DL-glutamic acid comprising preparing a solution containing one of said racemic modifications and an optically active form of the other, and separating solids comprising an optically active form of the racemic modification from the solution by crystallization.
- a process for resolving a racemic modification selected from the group consisting of DL-aspartic acid and DL-glutamic acid comprising preparing an aqueous solution supersaturated with one of said racemic modifications, and containing an optically active form of the other, and separating solids comprising an optically active form of the racemic modification from the solution by crystallization.
- a process for resolving DL-aspartic acid which comprises preparing an aqueous solution supersaturated with respect to DL-aspartic acid and also containing L-glutamic acid, and separatin solids comprising an optically active form of aspartic acid from the solution by crystallization at pH 3.1.
- a process for resolving DL-aspartic acid which comprises preparing an aqueous solution supersaturated with respect to DL-aspartic acid and saturated with L-glutamic acid, and separating solids comprising an optically active form of aspartic acid from the solution by crystallization at pH 3.1.
- a process for resolving DL-aspartic acid which comprises preparing an aqueous solution supersaturated with respect to DL-aspartic acid and also containing D-glutamic acid, and separating solids comprising an optically active form of aspartic acid from the solution by crystallization.
- a process for resolving DL-aspartic acid which comprises preparing an aqueous solution supersaturated with respect to DL-aspartic acid and saturated with D-glutamic acid, and separating solids comprising an optically active form of aspartic acid from the solution by crystallization.
- a process for resolving DL-glutamic acid which comprises preparing an aqueous solution supersaturated with respect to DL-glutamic acid and also containing L- aspartic acid, and separating solids comprising an optically active form of glutamic acid from the solution by crystallization at pH 3.2.
- a process for resolving DL-glutamic acid which comprises preparing an aqueous solution supersaturated with respect to DL-glutamic acid and saturated with L- aspartic acid, and separating solids comprising an optically active form of glutamic acid from the solution by crystallization at pH 3.2.
- a process for resolving DL-glutamic acid which comprises preparing an aqueous solution supersaturated with respect to DL-glutarnic acid and also containing D-aspartic acid, and separating solids comprising an optically active form of glutamic acid from the solution by crystallization.
- a process for resolving DL-glutamic acid which comprises preparing an aqueous solution supersaturated with respect to DL-glutamic acid and saturated with D- aspartic acid, and separating solids comprising an optically active form of glutamic acid from the solution by crystallization.
- a process for resolving DL-glutarnic acid which comprises preparing an aqueous solution supersaturated with respect to DL-glutamic acid and containing an optically active form of leucine, and separating solids comprising an optically active form of glutamic acid from the solution by crystallization.
Description
United States Patent 2,790,001 RESOLUTION OF AMINO ACIDS Joseph L. Purvis, Northbrook, Ill., assignor to Interna-- No Drawing. Application November 30, 1954, Serial No. 472,211
12 Claims. (Cl. 260-534) This invention relates to a process for resolving racemic modifications of optically active compounds, and more particularly, to the resolution of racemic modifications of alpha-amino carboxylic acids.
Glutamic acid and aspartic acid are well known optically active compounds. However, only L-glutamic acid and L-aspartic acid are useful at the present time, there being no known utility for D-glutamic acid and D-aspartic acid or their racemic modification; namely, DL-glutamic acid or DL-aspartic acid. Chemical processes for the synthesis of glutamic acid and aspartic acid, however, result in the formation of racemic modifications of these compounds, that is, optically neutral DL-glutamic acid and DL-aspartic acid, respectively. These racemic modifications, although having no value in commerce as such,
production of synthetic L-glutamic acid and L-aspartic acid has been the lack of a commercially feasible procedure for resolving racemic modifications of glutamic acid and-aspartic acid into their respective enantiomorphs.
One object of the instant invention is to provide a process for the resolution of DL-alpha-amino carboxylic acids.
Another object of the instant invention is to provide a process for the resolution of DL-glutamic acid.
Another object of this invention is to provide a process for the resolution of DL-aspartic acid.
Another object of this invention is to provide a process for the resolution of DL-leucine.
A further object of this invention is to provide a commercially feasible process for the resolution of DL-alphaamino carboxylic. acids which do not require the use of expensive reagents or equipment.
In accordance with this invention, a racemic modification of an alpha-amino carboxylic acid, such as, for example, aspartic acid, glutamic acid, or leucine, is resolved by preparing a solution containing the racemic modification and an optically active form of another alpha-amino carboxylic acid, and separating solids from the solution by crystallization. The crystals thus separated comprise a quantity of an optically active form of the racemic modification originally in the solution and a quantity of the racemic modification in the unresolved state with perhaps some of the optically activecform of the resolving compound; The optically active form of the racemic modification being subjected to the resolution process may be separated from the other compounds by standard procedures.
It is preferred to apply the process of this invention to the resolution of DL-alpha-amino carboxylic acids containing between about four and about nine carbon atoms and containing less than three carboxy groups, using as the resolving compound an optically active form of an alpha-amino carboxylic acid containing between about four and about nine carbon atoms and containing less in the molecule.
than three carboxy groups. Alpha-amino carboxylic acids which are particularly useful in this invention are those having a solubility in water at room temperature of less than about 8 grams per 100 grams of water. Specific alpha-amino carboxylic acids, in addition to leucine, aspartic acid and glutamic acid, which may be utilized include tyrosine, isoleucine, norleucine, valine, and the like. All of these compounds may be utilized as resolving compounds or may be resolved when in their racemic modifications according to the process of this invention. All of these compounds are characterized as non-basic alpha-amino carboxylic acids for the reason that all contain not more .than one amino group per carboxy group Alpha-amino carboxylic acids containing more than one amino group per carboxygroup in the molecule, such as lysine, are not operable in this invention.
"A preferred practice of the instant invention comprises preparing an aqueous solution of a racemic modification of either aspartic acid or glutamic acid, the solution also containing an optically active form of that one of these two compounds which is not being resolved. For example, if it is desired to resolve DL-aspartic acid in accordance with this invention, a solution is prepared containing DL-aspartic acid and an optically active form of, for example, glutamic acid, that is, either L-glutamic acid or D-glutamic acid. 'Alternatively, if it is desired to resolve DL-glutamic acid in accordance with this invention, a solution is prepared containing DL-glutamic acid and an optically 'active form of aspartic acid, that is, D-' aspartic acid or L-aspartic acid.
A convenient method for preparing the solution'com prises preparing an aqueous slurry of the racemic modification and an optically active form of the resolving com-' pound, for example, an aqueous slurry of DL-aspartic acid and L-glutamic acid, and adding alkali to the slurry in sufiicient amount to dissolve the solids and form a true solution. The solution is then adjusted to about the isoelectric point of the racemic modification by the addition of an inorganic acid, such as aqueous hydrochloric acid, and the volume of the solution is adjusted by adding or removing water so that the solution will be supersaturated with respect to the racemic modification at the isoelectric point. to crystallization contain between about 3% and about 5% of the racemic modification and between about 1% and about 2% of the resolving compound. The solution is then allowed to stand with gentle agitation until crystallization is complete. Crystallization is usually carried out at room temperature, but higher or lower temperatures may be utilized if desired. The crystals will cont-ain a substantial quantity of an optically active form of of the racemic modification corresponding in rotation to that of the resolving compound, and also a substantial quantity of the racemic modification.
-In accordance with a specific embodiment ofthis invention, DL-aspartic acid and L-glutamic acid are slurried in water, and aqueous sodium hydroxide is added to the slurry with agitation until the pH of the liquid phase is adjusted, preferably to about 7.0. Under these conditionsv the DL-aspartic acid and L-glutamic acid dissolve to form a true solution. The solutionis then adjusted to about.
. pH 3.1 by'the addition of concentrated aqueous hydrochloric acid, and the volumeof the solution is adjusted It is desirable that the solution being subjected armour by adding or removing (by evaporation) water so that the solution at pH 3.1 will be supersaturated with respect to DL-aspartic acid. The solution is then allowed to stand with gentle agitation for about 72 hours at room temperature and filtered. The crystals obtained comprise about 45% DL-aspartic acid, about 40% of D-aspartic acid, and about 15% QtL-gIutamic acid. The filtrate contains about 63% of the DL-aspart-ic acid originally in solution, about 8% L-aspartic acid (based upon total solids in solution) and about 90% of the L-glutamic acid originally added.
In carrying out the process of this invention, it is desirable that the crystallization be carried out at a temperature of about room temperature or below, but higher temperatures may be utilized for particular purposes. The solution of the racemic modification and the resolving compound may be prepared in any convenient manner so long as the solution upon adjustment to about the isoelectric point of the racemic modification is supersaturated with respect to the racemic modification. It is not necessary that the resolving compound be at its-saturation concentration at the time of crystallization if less than optimum resolution is permissible. The best yields, however, are obtained if the resolving compound is at its saturation concentration at the time that crystallization begins. Crystallization is carried out until the formation of crystals discontinues, that is, until equilibrium conditions obtain or are substantially achieved.
The term resolving compound as used herein refers to an optically active form of either glutamic acid or aspartic acid, or similar non-basic alpha-amino carboxylic acid, for example, L-aspartic acid, D-aspartic acid, L-glutamic acid, or D-glutamic acid, etc. When DL-aspartic acid is subjected to resolution in accordance with this invention, the resolving compound is preferably either L-glutamic acid or D-glutamic acid. Conversely, when DL-glutamic acid is resolved in accordance with this invention, the resolving compound is preferably L-aspartic acid or D- aspartic acid.
, T he following examples representspecifieembodiments ofthis invention. Allparts and percentages are by weight unless otherwise indicated.
Example I About 1'0'parts of DL-asparatic acid and about '5 parts of L=glutamic acid were slurried with about 200 parts water. To the slurry was added a 50% aqueous of sodium hydroxide until the 'pH of the aqueous phase amounted to about 7.0. Addition of the sodium hydroxide solution "resulted in the dissolution of the DL-aspartic acid and L-glutamic acid to form a true solution. The solution was adjusted to pH 3.1 by the addition of 37% aqueous hydrochloric acid and then sufficient water was added to the solution to adjust the weight of the solution to 250parts. The solution was allowed to stand with gentle agitation for about 72 hours at room temperature and then filtered to remove the crystals which had formed. The crystals amounted to 5.8 parts and had the following composition by weight:
Percent D-aspartic acid 37.0 DL-aspartic acid. 54.5 L-glutamic acid 8.5
The .filtrate amounted to 240 parts and contained :the following solids:
Parts L-aspartic acid--. 2.1 DL-aspartic acid 2.6 Lvglutamic acid 4.4
glutamic acid by re-crystallizing the D-aspartic acid at its i'soelectric point (pH 3.1).
The L-aspartic acid was isolated from the filtrate by first separating L-glutamic acid by crystallization of L- glutamic acid hydrochloride, adjusting the pH to 3.1 and erystallizing L-aspartic acid.
Example 11 Twelve parts DL-aspartic acid and 8 parts L-glutamic acid were slurried in Water and dissolved by adjusting the pH of the aqueous phase to about 7.0 by the addition of a 50% aqueous solution of sodium hydroxide. The solution was then adjusted to pH 3.2 by the addition of 30% aqueous hydrochloric acid, and the weight of the solution was then adjusted to 400 parts by adding water. The solution was allowed to stand with gentle agitation for about 72 hours and then filtered to remove the crystals which had formed. The crystals amounted to 3.5 parts and had the following compositions:
Percent D-aspartic acid 40 DL-aspartic acid 45 L-glutamic acid 15 The filtrate amounted to 393 parts and contained the following solids:
Parts L-aspartic acid 1.4 DL-aspartic acid 7.6 L-glutamic acid 7.2
The optically active forms of aspartic acid and glutamic acid were recovered by the procedures outlined in Example I.
Example III About 10 parts of DL-glutamic acid and about 5 parts of L-aspartic acid were slurried in about 200 parts water. To the slurry was added a. 5 0% aqueous solution of sodium hydroxide until the pH of the aqueous phase amounted to about 7.0. Addition of the sodium hydroxide solution resulted'in dissolution of the DL-glutamic acid and L- aspartic acid to form a true solution. The solution was adjusted to pH 3.2 by the addition of 37% aqueous hydrochloric acid and then suificient water was added to the solution to adjust the weight of the solution ;to 250 parts. The solution was allowed to stand with gentle agitation for about 72 hours at room temperature and then filtered to remove the crystals which had formed. The crystals amounted to about 5 parts and had the following composition by weight:
Percent D-glutarnic acid 10 DL-glutamic acid 78 L-aspartic acid 12 Example TV About 16.8 parts of DL-glutamic acid monohydrate and about 9 parts of L-leucine were dissolved in dilute hydrochloric acid at pH 1.0. The solution was :then adjusted to pH 3.2 by the addition of a 50% aqueous sodium hydroxide solution. The final solution amounted to about 300 parts. The solution was agitated gently over a period of about 24'hours at about 25 C. to per mit crystallization to proceed, and the crystals were re moved by filtration. The crystals amounted to 9.4 parts and comprised 1.8 parts D-glutamic acid and 7.6 parts DL-glutamic acid. The Drglutamic acid was separated from the .DL-glutamic acid by recrystallization from 300 parts of water at about 25 C.
Having thus fully described and illustrated the character of theinstant invention, What is desired to be secured and claimed by Letters Patentis:
1. A process forresolvinga racemic-modification of :a non-basic alpha-amino 'carboxylic acid comprising prc paring a solution containing said racemic modification and an optically active .form of another non-basic alphaamino carboxylic acid, and separating solids comprising an optically active form of the racemic modification from the solution by crystallization.
2. A process for resolving a racemic modification se lected from the group consisting of DL-aspartic acid and DL-glutamic acid, comprising preparing a solution containing one of said racemic modifications and an optically active form of the other, and separating solids comprising an optically active form of the racemic modification from the solution by crystallization.
3. A process for resolving a racemic modification selected from the group consisting of DL-aspartic acid and DL-glutamic acid, comprising preparing an aqueous solution supersaturated with one of said racemic modifications, and containing an optically active form of the other, and separating solids comprising an optically active form of the racemic modification from the solution by crystallization.
4. A process for resolving DL-aspartic acid which comprises preparing an aqueous solution supersaturated with respect to DL-aspartic acid and also containing L-glutamic acid, and separatin solids comprising an optically active form of aspartic acid from the solution by crystallization at pH 3.1.
5. A process for resolving DL-aspartic acid which comprises preparing an aqueous solution supersaturated with respect to DL-aspartic acid and saturated with L-glutamic acid, and separating solids comprising an optically active form of aspartic acid from the solution by crystallization at pH 3.1.
6. A process for resolving DL-aspartic acid which comprises preparing an aqueous solution supersaturated with respect to DL-aspartic acid and also containing D-glutamic acid, and separating solids comprising an optically active form of aspartic acid from the solution by crystallization.
7. A process for resolving DL-aspartic acid which comprises preparing an aqueous solution supersaturated with respect to DL-aspartic acid and saturated with D-glutamic acid, and separating solids comprising an optically active form of aspartic acid from the solution by crystallization.
8. A process for resolving DL-glutamic acid which comprises preparing an aqueous solution supersaturated with respect to DL-glutamic acid and also containing L- aspartic acid, and separating solids comprising an optically active form of glutamic acid from the solution by crystallization at pH 3.2.
9. A process for resolving DL-glutamic acid which comprises preparing an aqueous solution supersaturated with respect to DL-glutamic acid and saturated with L- aspartic acid, and separating solids comprising an optically active form of glutamic acid from the solution by crystallization at pH 3.2.
10. A process for resolving DL-glutamic acid which comprises preparing an aqueous solution supersaturated with respect to DL-glutarnic acid and also containing D-aspartic acid, and separating solids comprising an optically active form of glutamic acid from the solution by crystallization.
11. A process for resolving DL-glutamic acid which comprises preparing an aqueous solution supersaturated with respect to DL-glutamic acid and saturated with D- aspartic acid, and separating solids comprising an optically active form of glutamic acid from the solution by crystallization.
12. A process for resolving DL-glutarnic acid which comprises preparing an aqueous solution supersaturated with respect to DL-glutamic acid and containing an optically active form of leucine, and separating solids comprising an optically active form of glutamic acid from the solution by crystallization.
References Cited in the file of this patent UNITED STATES PATENTS Emmick et al Jan. 2, 1951 Wiedman July 13, 1954 OTHER REFERENCES
Claims (1)
1. A PROCESS FOR RESOLVING A RACEMIC MODIFICATION OF A NON-BASIC ALPHA-AMINO CARBOXYLIC ACID COMPRISING PREPARING A SOLUTION CONTAINING SAID RACEMIC MODIFICATION AND AN OPTICALLY ACTIVE FORM OF ANOTHER NON-BASIC ALPHAAMINO CARBOXYLIC ACID, AND SEPARATING SOLIDS COMPRISING AN OPTICALLY ACTIVE FORM OF THE RACEMIC MODIFICATION FROM THE SOLUTON BY CRYSTALLIZATION.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US472211A US2790001A (en) | 1954-11-30 | 1954-11-30 | Resolution of amino acids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US472211A US2790001A (en) | 1954-11-30 | 1954-11-30 | Resolution of amino acids |
Publications (1)
Publication Number | Publication Date |
---|---|
US2790001A true US2790001A (en) | 1957-04-23 |
Family
ID=23874598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US472211A Expired - Lifetime US2790001A (en) | 1954-11-30 | 1954-11-30 | Resolution of amino acids |
Country Status (1)
Country | Link |
---|---|
US (1) | US2790001A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2882302A (en) * | 1957-04-29 | 1959-04-14 | Int Minerals & Chem Corp | Purification of glutamic acid enantiomorphs |
US3192233A (en) * | 1961-10-20 | 1965-06-29 | Int Minerals & Chem Corp | Selective oxidation of acrolein dimer |
US4093653A (en) * | 1975-12-09 | 1978-06-06 | Stamicarbon, B.V. | Process for the preparation of optically active phenyl glycine amide |
US4094904A (en) * | 1975-12-09 | 1978-06-13 | Stamicarbon, B.V. | Process of racemizing an optically active phenyl glycine amide with or without a substituted phenyl group |
DE3122537A1 (en) * | 1980-06-08 | 1982-03-18 | Yeda Research And Development Co., Ltd., Rehovot | METHOD FOR SEPARATING MIXTURES FROM D- AND L-AMINO ACIDS |
US4399304A (en) * | 1979-12-05 | 1983-08-16 | Ajinomoto Company Incorporated | L-phenylalanine 1/2 sulfate and its use |
EP0225503A1 (en) * | 1985-11-12 | 1987-06-16 | Yeda Research And Development Company Limited | Resolution system |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2536360A (en) * | 1949-11-25 | 1951-01-02 | Du Pont | Racemization of lysine |
US2683739A (en) * | 1952-03-03 | 1954-07-13 | Int Minerals & Chem Corp | Process for the crystallization of l-glutamic acid |
-
1954
- 1954-11-30 US US472211A patent/US2790001A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2536360A (en) * | 1949-11-25 | 1951-01-02 | Du Pont | Racemization of lysine |
US2683739A (en) * | 1952-03-03 | 1954-07-13 | Int Minerals & Chem Corp | Process for the crystallization of l-glutamic acid |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2882302A (en) * | 1957-04-29 | 1959-04-14 | Int Minerals & Chem Corp | Purification of glutamic acid enantiomorphs |
US3192233A (en) * | 1961-10-20 | 1965-06-29 | Int Minerals & Chem Corp | Selective oxidation of acrolein dimer |
US4093653A (en) * | 1975-12-09 | 1978-06-06 | Stamicarbon, B.V. | Process for the preparation of optically active phenyl glycine amide |
US4094904A (en) * | 1975-12-09 | 1978-06-13 | Stamicarbon, B.V. | Process of racemizing an optically active phenyl glycine amide with or without a substituted phenyl group |
US4399304A (en) * | 1979-12-05 | 1983-08-16 | Ajinomoto Company Incorporated | L-phenylalanine 1/2 sulfate and its use |
DE3122537A1 (en) * | 1980-06-08 | 1982-03-18 | Yeda Research And Development Co., Ltd., Rehovot | METHOD FOR SEPARATING MIXTURES FROM D- AND L-AMINO ACIDS |
US4390722A (en) * | 1980-06-08 | 1983-06-28 | Yeda Research And Development Company Ltd. | Resolution of amino acids |
US4533506A (en) * | 1980-06-08 | 1985-08-06 | Yeda Research And Development Company Ltd. | Resolution of amino acids |
EP0225503A1 (en) * | 1985-11-12 | 1987-06-16 | Yeda Research And Development Company Limited | Resolution system |
US4864031A (en) * | 1985-11-12 | 1989-09-05 | Yeda Research And Development Co., Ltd. | Process for the resolution of D,L-racemic mixtures |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Addadi et al. | Useful impurities for optical resolutions. 2. Generality and mechanism of the rule of reversal | |
US2790001A (en) | Resolution of amino acids | |
EP0119804B1 (en) | Novel method for optical resolution of dl-alpha-amino acid or (+)-alpha-phenylethanesulfonic acid | |
US2556907A (en) | Resolution of lysine | |
US2945049A (en) | Salts of basic amino acids and linoleic acid | |
US2657230A (en) | Resolution of lysine | |
US3028430A (en) | Process for the production of optically active isomers of amphetamine | |
US2851482A (en) | L-arginine-l-glutamate | |
US4390722A (en) | Resolution of amino acids | |
US2984684A (en) | Resolution of dl-glutamic acid | |
US3933902A (en) | Method for the optical resolution of DL-αphenylglycine | |
US3994962A (en) | Method of manufacturing optically active p-hydroxyphenylglycine | |
US2882302A (en) | Purification of glutamic acid enantiomorphs | |
US4847409A (en) | Recovery of L-amino acid isomers from their racemic mixtures | |
DE2547548A1 (en) | OPTICAL CLEAVAGE OF PHENYLGLYCINAMIDE | |
US3529022A (en) | Process for resolution of optical isomers of racemic ammonium pantoate by preferential crystallization | |
US3591579A (en) | Resolution of amino-caprolactams | |
US4542236A (en) | Process for preparing optically active phenylalanine | |
US2942024A (en) | Resolution of lysine | |
US3607929A (en) | Increasing the optical purity of l-lysine monohydrochloride | |
US3925454A (en) | Preparation of optically active isomers of lysines | |
US3932491A (en) | Process for optical resolution of racemic lysine sulphanilate | |
US2937200A (en) | Resolution of dl-glutamic acid | |
US3542766A (en) | Resolution of alpha-aminocaprolactam and n-carbamoyl-valine | |
US3912738A (en) | Isomers of N,N{40 -bis-{8 (1-formamido-2,2,2-trichloro)-ethyl{9 -piperazine and method of isolating the same |